Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Epic Bio emerges to engineer epigenetics

by Jessica Marshall
July 14, 2022 | A version of this story appeared in Volume 100, Issue 25

 

Backed by $55 million of series A funding, Epic Bio has launched to treat disease by regulating gene expression. Epic’s founder is Stanford University professor Stanley Qi, who is named as a coinventor on the University of California’s CRISPR gene-editing patent. The company’s technologies include a library of gene-expression modulators and the ability to design guide RNAs that target genes. It has also licensed from Stanford a small DNA-binding protein, called CasMINI, that will help deliver therapies to target organs.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.